Scorpius Holdings Achieves 16% Year-Over-Year Increase in Revenue for the Second Quarter of 2024
Scorpius Holdings (NYSE American: SCPX) reported a 16% year-over-year revenue increase and a 25% reduction in operating expenses for Q2 2024. The company's pipeline now exceeds $100 million in weighted opportunities across government and manufacturing sectors. Q2 2024 financial highlights include:
- Revenue: $0.8 million (up from $0.7 million in Q2 2023)
- Cost of revenues: $0.8 million (up from $0.4 million)
- R&D expenses: $3.6 million (down from $5.2 million)
- SG&A expenses: $5.0 million (down from $7.0 million)
- Net loss: $8.9 million or ($26.98) per share (improved from $13.9 million or ($106.67) per share)
As of August 19, 2024, Scorpius had approximately $13.2 million in cash and short-term investments, strengthening its balance sheet to capitalize on upcoming projects and potentially achieve positive cash flow.
Scorpius Holdings (NYSE American: SCPX) ha registrato un aumento del fatturato del 16% rispetto all'anno precedente e una riduzione del 25% delle spese operative per il secondo trimestre del 2024. Il portafoglio dell'azienda supera ora i 100 milioni di dollari in opportunità ponderate nei settori pubblico e manifatturiero. I punti salienti finanziari del secondo trimestre del 2024 includono:
- Fatturato: 0,8 milioni di dollari (in aumento rispetto a 0,7 milioni di dollari nel Q2 2023)
- Costo del fatturato: 0,8 milioni di dollari (in aumento rispetto a 0,4 milioni di dollari)
- Spese R&S: 3,6 milioni di dollari (in diminuzione rispetto a 5,2 milioni di dollari)
- Spese SG&A: 5,0 milioni di dollari (in diminuzione rispetto a 7,0 milioni di dollari)
- Perdita netta: 8,9 milioni di dollari o (26,98 dollari) per azione (migliorata rispetto a 13,9 milioni di dollari o (106,67 dollari) per azione)
Al 19 agosto 2024, Scorpius disponeva di circa 13,2 milioni di dollari in contante e investimenti a breve termine, rafforzando il suo bilancio per capitalizzare i progetti futuri e potenzialmente raggiungere un flusso di cassa positivo.
Scorpius Holdings (NYSE American: SCPX) reportó un aumento del 16% en los ingresos interanuales y una reducción del 25% en los gastos operativos para el segundo trimestre de 2024. El pipeline de la compañía ahora supera los 100 millones de dólares en oportunidades ponderadas en los sectores gubernamental e industrial. Los aspectos destacados financieros del segundo trimestre de 2024 incluyen:
- Ingresos: 0,8 millones de dólares (aumento desde 0,7 millones en el Q2 2023)
- Costo de ingresos: 0,8 millones de dólares (aumento desde 0,4 millones)
- Gastos en I+D: 3,6 millones de dólares (disminución desde 5,2 millones)
- Gastos SG&A: 5,0 millones de dólares (disminución desde 7,0 millones)
- Pérdida neta: 8,9 millones de dólares o (26,98 dólares) por acción (mejora desde 13,9 millones de dólares o (106,67 dólares) por acción)
Al 19 de agosto de 2024, Scorpius tenía aproximadamente 13,2 millones de dólares en efectivo e inversiones a corto plazo, fortaleciendo su balance para capitalizar sobre próximos proyectos y potencialmente lograr un flujo de caja positivo.
Scorpius Holdings (NYSE American: SCPX)는 2024년 2분기에 전년 대비 16% 증가한 매출과 25% 감소한 운영비용을 보고했습니다. 회사의 파이프라인은 이제 정부 및 제조 분야에서 1억 달러를 초과하는 가중 기회를 보유하고 있습니다. 2024년 2분기 재무 하이라이트는 다음과 같습니다:
- 매출: 80만 달러 (2023년 2분기의 70만 달러에서 증가)
- 매출 원가: 80만 달러 (40만 달러에서 증가)
- 연구개발 비용: 360만 달러 (520만 달러에서 감소)
- 판관비: 500만 달러 (700만 달러에서 감소)
- 순손실: 890만 달러 또는 주당 (26.98달러) (1,390만 달러 또는 주당 (106.67달러)에서 개선됨)
2024년 8월 19일 기준으로, Scorpius는 약 1320만 달러의 현금 및 단기 투자를 보유하고 있어 향후 프로젝트를 활용하고 긍정적인 현금 흐름을 달성할 수 있는 탄탄한 재무 상태를 구축하고 있습니다.
Scorpius Holdings (NYSE American: SCPX) a annoncé une augmentation de 16% de son chiffre d'affaires par rapport à l'année précédente et une réduction de 25% de ses dépenses opérationnelles pour le deuxième trimestre de 2024. Le pipeline de l'entreprise dépasse maintenant 100 millions de dollars en opportunités pondérées dans les secteurs gouvernemental et industriel. Les faits saillants financiers du deuxième trimestre de 2024 incluent :
- Chiffre d'affaires : 0,8 million de dollars (en hausse par rapport à 0,7 million de dollars au T2 2023)
- Coût des revenus : 0,8 million de dollars (en hausse par rapport à 0,4 million de dollars)
- Dépenses R&D : 3,6 millions de dollars (en baisse par rapport à 5,2 millions de dollars)
- Dépenses SG&A : 5,0 millions de dollars (en baisse par rapport à 7,0 millions de dollars)
- Perte nette : 8,9 millions de dollars ou (26,98 dollars) par action (améliorée par rapport à 13,9 millions de dollars ou (106,67 dollars) par action)
Au 19 août 2024, Scorpius disposait d'environ 13,2 millions de dollars en liquidités et investissements à court terme, renforçant ainsi son bilan pour tirer parti des projets à venir et potentiellement atteindre un flux de trésorerie positif.
Scorpius Holdings (NYSE American: SCPX) hat im zweiten Quartal 2024 einen Umsatzanstieg von 16% im Jahresvergleich und eine Reduzierung der Betriebskosten um 25% gemeldet. Die Pipeline des Unternehmens übersteigt nun 100 Millionen Dollar an gewichteten Möglichkeiten in den Bereichen Regierung und Manufacturing. Die finanziellen Höhepunkte des zweiten Quartals 2024 umfassen:
- Umsatz: 0,8 Millionen Dollar (im Vergleich zu 0,7 Millionen Dollar im Q2 2023)
- Kosten der Umsätze: 0,8 Millionen Dollar (im Vergleich zu 0,4 Millionen Dollar)
- F&E-Ausgaben: 3,6 Millionen Dollar (im Vergleich zu 5,2 Millionen Dollar)
- SG&A-Ausgaben: 5,0 Millionen Dollar (im Vergleich zu 7,0 Millionen Dollar)
- Nettoverlust: 8,9 Millionen Dollar oder (26,98 Dollar) pro Aktie (verbessert von 13,9 Millionen Dollar oder (106,67 Dollar) pro Aktie)
Zum 19. August 2024 verfügte Scorpius über etwa 13,2 Millionen Dollar in Bar- und kurzfristigen Investitionen, was das Eigenkapital stärkt, um von bevorstehenden Projekten zu profitieren und möglicherweise einen positiven Cashflow zu erreichen.
- 16% year-over-year increase in revenue for Q2 2024
- 25% reduction in operating expenses compared to Q2 2023
- Pipeline surpasses $100 million in weighted opportunities
- Decrease in R&D expenses from $5.2 million to $3.6 million
- Reduction in SG&A expenses from $7.0 million to $5.0 million
- Improvement in net loss from $13.9 million to $8.9 million
- Cash and short-term investments increased to $13.2 million as of August 19, 2024
- Net loss of $8.9 million for Q2 2024
- Increase in cost of revenues from $0.4 million to $0.8 million
- Total non-operating expense of $0.6 million, including loss on disposal of leasehold improvements
Insights
Scorpius Holdings' Q2 2024 results show a mixed financial picture. The
The
Scorpius Holdings' focus on the CDMO sector positions it in a growing market, driven by increasing outsourcing trends in the pharmaceutical and biotech industries. The company's ability to grow revenue in a challenging quarter suggests some resilience in demand for its services. The
However, the company's small size and financial constraints may limit its ability to compete with larger, more established CDMOs. The recent financing provides a lifeline, but sustained growth and profitability will be important for long-term success. Investors should closely monitor Scorpius' ability to convert pipeline opportunities into actual revenues and its progress towards positive cash flow, as these will be key indicators of the company's viability in this competitive market.
Reduces operating expenses by
Pipeline surpasses
DURHAM, N.C., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today provided strategic, financial, and operational updates for the second quarter ended June 30, 2024.
Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, “We are extremely proud of the progress Scorpius achieved in the second quarter of 2024. Despite facing a quarter with significant working capital challenges, our revenues still increased by
“Our success this year highlights the significant progress we’ve made in both innovation and customer-focused program management across our service platforms. This progress is most clearly reflected in the strength of our pipeline, which now surpasses
Second Quarter 2024 Financial Results
For the three months ended June 30, 2024, the Company recognized
Cost of revenues were
Research and development expenses were
Selling, general and administrative expenses were
For the three months ended June 30, 2024, there was no change in fair value of contingent earn-out receivable, related party.
Total non-operating expense was (
Net loss attributable to Scorpius was approximately
As of June 30, 2024, the Company had approximately
Scorpius Holdings, Inc.
Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements such as being able to capitalize on a number of exciting projects in front of the Company, the funding allowing the Company to accelerate its revenue growth and enable it to achieve its goal of positive cash flow, the Company’s pipeline, surpassing
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
ir@scorpiusbiologics.com
FAQ
What was Scorpius Holdings' (SCPX) revenue growth in Q2 2024?
How much did Scorpius Holdings (SCPX) reduce its operating expenses in Q2 2024?
What is the current value of Scorpius Holdings' (SCPX) pipeline opportunities?
What was Scorpius Holdings' (SCPX) net loss for Q2 2024?